Garching / Munich, September 23, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that they will provide new data for Lu-edotreotide (ITM-11) in two poster presentations at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, held from September 26 – 30, 2026 in Boston, Massachusetts. One poster will feature Phase 3 COMPETE trial dosimetry results for 177Lu-edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A second poster will highlight findings from a registry analysis of re-treatment with 177Lu-edotreotide in patients with progressive neuroendocrine tumors (NETs).